順天醫藥生技股份有限公司
順天醫藥生技股份有限公司為研發型生技公司，核心產品為長效止痛針劑「納疼解」。目前重點研發管線包括治療急性缺血性中風的新藥 LT3001，致力於在神經與腫瘤領域開發具高度競爭力之藥物。公司成立於 2000 年，總部位於台灣台北。
今日下跌 4.34%，股價跌破短期均線。該股 RSI(6) 為 38.2，處於中性區間，短線無明顯超買超賣訊號。股價跌破5日、20日、60日、120日均線。KD 指標中性（K=49.6）；MACD 柱狀體為正值，維持多方動能。 （自動產生 · 非投資建議）
| 日期 | 外資 | 投信 | 自營商 | 合計 |
|---|---|---|---|---|
| 08-12 | -100 | -30 | +4 | -130 |
| 08-11 | +79 | -30 | +2 | +49 |
| 08-10 | +1 | -30 | 0 | -28 |
| 08-07 | +16 | -30 | +1 | -15 |
| 08-06 | +28 | -30 | 0 | -2 |
| 08-05 | +78 | -30 | +4 | +49 |
| 08-04 | -36 | -30 | +2 | -66 |
| 08-03 | +48 | -30 | 0 | +18 |
| 07-31 | -65 | -30 | 0 | -95 |
| 07-30 | +8 | -30 | 0 | -22 |
| 07-29 | +28 | -30 | +2 | -2 |
| 07-28 | +17 | -30 | +2 | -13 |
| 07-27 | +27 | -30 | +1 | -3 |
| 07-24 | +24 | -30 | +1 | -6 |
| 07-23 | -11 | -30 | +2 | -42 |
| 07-22 | +20 | 0 | +2 | +20 |
| 07-21 | +112 | -30 | +4 | +80 |
| 07-20 | +68 | -30 | +2 | +35 |
| 07-17 | -46 | -30 | +3 | -76 |
| 07-16 | +28 | -30 | 0 | -4 |
| 07-15 | +45 | -30 | 0 | +13 |
| 07-14 | -44 | -30 | +2 | -74 |
| 07-13 | -25 | -30 | 0 | -55 |
| 07-09 | +14 | -30 | +9 | -7 |
| 07-08 | -68 | -30 | 0 | -98 |
| 07-07 | +12 | 0 | 0 | +12 |
| 07-06 | -317 | 0 | 0 | -324 |
| 07-03 | +82 | -30 | +13 | +58 |
| 07-02 | -11 | -30 | 0 | -41 |
| 07-01 | +40 | -30 | 0 | +10 |
| 06-30 | +48 | -30 | 0 | +18 |
| 06-29 | +86 | -30 | 0 | +56 |
| 06-26 | -18 | -30 | +2 | -47 |
| 06-25 | -43 | 0 | 0 | -43 |
| 06-24 | +46 | -30 | +1 | +16 |
| 06-23 | +90 | -30 | 0 | +60 |
| 06-22 | +130 | -30 | +2 | +100 |
| 06-18 | +157 | -30 | +4 | +127 |
| 06-17 | +7 | -30 | +4 | -23 |
| 06-16 | +102 | -30 | +4 | +73 |
| 06-15 | +24 | 0 | +4 | +24 |
| 06-12 | +70 | 0 | 0 | +70 |
| 06-11 | +82 | 0 | +4 | +82 |
| 06-10 | +48 | 0 | +4 | +48 |
| 06-09 | -32 | 0 | +2 | -33 |
| 06-08 | -11 | 0 | +2 | -10 |
| 06-05 | -89 | 0 | +8 | -89 |
| 06-04 | -60 | 0 | +6 | -60 |
| 06-03 | -124 | 0 | +16 | -124 |
| 06-02 | -85 | 0 | +20 | -85 |
| 06-01 | -92 | 0 | +6 | -92 |
| 05-29 | -37 | 0 | 0 | -38 |
| 月份 | 營收 | MoM% | YoY% |
|---|---|---|---|
| 2026/04 | 8 萬 | -84.5% | -83.4% |
| 2026/03 | 50 萬 | +1576.7% | -94.3% |
| 2026/02 | 3 萬 | -99.2% | -25.0% |
| 2026/01 | 395 萬 | -71.7% | +9777.5% |
| 2025/12 | 1396 萬 | +7971.7% | -19.3% |
| 2025/11 | 17 萬 | 0.0% | -95.8% |
| 2025/10 | 17 萬 | -96.0% | +332.5% |
| 2025/09 | 427 萬 | +2367.6% | +1056.9% |
| 2025/08 | 17 萬 | -97.6% | +332.5% |
| 2025/07 | 726 萬 | +387.1% | +21.8% |
| 2025/06 | 149 萬 | +577.7% | +297.6% |
| 2025/05 | 22 萬 | - | -94.9% |